Rayan Kabirian, Olivier Tredan, Frederik Marmé, Xavier Paoletti, Lauriane Eberst, Coriolan Lebreton, Thibault De La Motte Rouge, Renaud Sabatier, Antoine Angelergues, Michel Fabbro, Toon Van Gorp, Laura Mansi, Laurence Gladieff, Emilie Kaczmarek, Jérôme Alexandre, Thomas Grellety, Laure Favier, Julia Welz, Jean-Sébastien Frenel, Alexandra Leary
{"title":"TEDOVA:疫苗 OSE2101 +/- pembrolizumab 用于铂敏感复发性卵巢癌的维持治疗。","authors":"Rayan Kabirian, Olivier Tredan, Frederik Marmé, Xavier Paoletti, Lauriane Eberst, Coriolan Lebreton, Thibault De La Motte Rouge, Renaud Sabatier, Antoine Angelergues, Michel Fabbro, Toon Van Gorp, Laura Mansi, Laurence Gladieff, Emilie Kaczmarek, Jérôme Alexandre, Thomas Grellety, Laure Favier, Julia Welz, Jean-Sébastien Frenel, Alexandra Leary","doi":"10.1080/14796694.2024.2386922","DOIUrl":null,"url":null,"abstract":"<p><p>Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.<b>Clinical Trial Registration:</b> NCT04713514 (ClinicalTrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.\",\"authors\":\"Rayan Kabirian, Olivier Tredan, Frederik Marmé, Xavier Paoletti, Lauriane Eberst, Coriolan Lebreton, Thibault De La Motte Rouge, Renaud Sabatier, Antoine Angelergues, Michel Fabbro, Toon Van Gorp, Laura Mansi, Laurence Gladieff, Emilie Kaczmarek, Jérôme Alexandre, Thomas Grellety, Laure Favier, Julia Welz, Jean-Sébastien Frenel, Alexandra Leary\",\"doi\":\"10.1080/14796694.2024.2386922\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.<b>Clinical Trial Registration:</b> NCT04713514 (ClinicalTrials.gov).</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2024.2386922\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2386922","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
卵巢癌是全球妇科癌症的主要死因。铂类化疗是治疗的基础。对于一线化疗和随后的复发,可采用维持策略来延长化疗的间隔时间。目前的维持疗法包括贝伐单抗和多聚 ADP 核糖聚合酶抑制剂,但这些疗法只能在病程中使用一次。使用多聚 ADP 核糖聚合酶抑制剂和贝伐单抗后首次或第二次铂敏感复发的患者是一个尚未满足医疗需求的领域。这项由学术界赞助的国际 II 期随机试验正在评估一种治疗性癌症疫苗(OSE2101)与抗 PD1(pembrolizumab)的联合疗法,作为铂敏感复发患者的维持疗法,无论患者既往接受过多少次铂类化疗,且铂类化疗后未出现进展:临床试验注册:NCT04713514(ClinicalTrials.gov)。
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.
Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.Clinical Trial Registration: NCT04713514 (ClinicalTrials.gov).
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.